Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge.

Journal article

Novel candidate HIV-1 vaccines have been constructed, which are tailor-designed for HLA-B*5101(+) patients infected with HIV-1 clade B. These vaccines employ novel immunogen HIVB-B*5101 derived from consensus HIV-1 clade B Gag p17 and p24 regions coupled to two Pol-derived B*5101-restricted epitopes, which are together with a third B*5101 epitope in Gag dominant in HIV-1-infected long-term non-progressing patients. Both plasmid DNA and modified vaccinia virus Ankara (MVA) vectors supported hi...

Expand abstract

Authors: Roshorm, Y; Hong, J; Kobayashi, N; Mcmichael, A; Volsky, D

• Publication status: Published
• Journal: European journal of immunology
• Volume: 39
• Issue: 7
• Pages: 1831-1840
• Publication date: 2009-07-01
• DOI: 10.1002/eji.200939309
• EISSN: 1521-4141
• ISSN: 0014-2980
• Language: English
• Keywords: Amino Acid Sequence; gag Gene Products, Human Immunodeficiency Virus; Humans; HLA-B Antigens; Epitopes; Interferon-gamma; HIV Antigens; Mice; Animals; Mice, Inbred BALB C; Female; HIV Infections; Blotting, Western; CD8-Positive T-Lymphocytes; Fusion Proteins, gag-pol; HIV-1; AIDS Vaccines; Flow Cytometry; Tumor Necrosis Factor-alpha; DNA, Recombinant; HIV Core Protein p24; Mice, Inbred CBA